A U.S. Post-Approval Study of the PROMUS Element Plus Everolimus-Eluting Platinum Chromium Coronary Stent System

Trial Profile

A U.S. Post-Approval Study of the PROMUS Element Plus Everolimus-Eluting Platinum Chromium Coronary Stent System

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 15 Mar 2017

At a glance

  • Drugs Everolimus (Primary) ; Aspirin; Clopidogrel; Prasugrel; Ticagrelor; Ticlopidine
  • Indications Coronary disorders; Coronary stent thrombosis; Myocardial ischaemia
  • Focus Therapeutic Use
  • Acronyms PE Plus PAS
  • Sponsors Boston Scientific Corporation
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 Dec 2015 Results published in the American Journal of Cardiology
    • 19 Jun 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top